Latest News and Press Releases

OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer

Les résultats de Topline seront présentés par le Pr Alexandra Leary, PhD, le 30 mai 2026 au congrès annuel de l’American Society of Clinical Oncology (ASCO) à ChicagoOSE Immunotherapeutics organisera...

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Her3-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Mesothelin-Targeted Immunotherapies" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...

TORONTO, May 08, 2026 (GLOBE NEWSWIRE) -- On World Ovarian Cancer Day the Global Ovarian Cancer Research Consortium, of which Ovarian Cancer Canada is a founding partner, today announced the launch...

TORONTO, 08 mai 2026 (GLOBE NEWSWIRE) -- À l’occasion de la Journée mondiale du cancer de l’ovaire, le Consortium international de recherche sur le cancer de l’ovaire, dont Cancer de l’ovaire Canada...

OCALA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the Final Primary Endpoint Report on Objective Response Rate data from...

This research investment will enable Dr. Jeanette Boudreau to prepare powerful natural killer cell immunotherapy to move into clinical trials

 -Trial Combines LIXTE’s LB-100 with Dostarlimab; Results Give Patients New Hope for a Challenging Disease with Limited Therapeutic Options- BOCA RATON, Fla., April 13, 2026 (GLOBE NEWSWIRE) --...

RESEARCH TRIANGLE PARK, N.C., April 08, 2026 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for...